Lexicon Pharmaceuticals Inc
General ticker "LXRX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $276.0M
Lexicon Pharmaceuticals Inc does not follow the US Stock Market performance with the rate: -14.0%.
Estimated limits based on current volatility of 8.3%: low 0.67$, high 0.79$
Factors to consider:
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [0.91$, 2.46$]
- 2024-12-30 to 2025-12-30 estimated range: [1.26$, 3.09$]
Financial Metrics affecting the LXRX estimates:
- Negative: Non-GAAP EPS, $ of -0.80 <= 0.10
- Negative: Operating profit margin, % of -99.30 <= 1.03
- Negative: negative Net income
- Positive: -0.96 < Investing cash flow per share, $ of -0.23
- Negative: Operating cash flow per share per price, % of -37.54 <= 2.35
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Interest expense per share, $ of 0.06 <= 0.14
- Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85
- Negative: Industry earnings per price (median), % of -26.04 <= 1.31
Short-term LXRX quotes
Long-term LXRX plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $0.30MM | $0.14MM | $1.20MM |
| Operating Expenses | $87.39MM | $100.90MM | $172.95MM |
| Operating Income | $-87.09MM | $-100.76MM | $-171.75MM |
| Non-Operating Income | $-0.67MM | $-1.18MM | $-5.37MM |
| Interest Expense | $0.80MM | $2.78MM | $13.10MM |
| R&D Expense | $55.05MM | $52.82MM | $58.89MM |
| Income(Loss) | $-87.76MM | $-101.94MM | $-177.12MM |
| Taxes | $0.51MM | $1.18MM | $0.00MM |
| Profit(Loss) | $-88.27MM | $-103.13MM | $-177.12MM |
| Stockholders Equity | $113.59MM | $117.12MM | $93.11MM |
| Inventory | $0.00MM | $0.00MM | $0.38MM |
| Assets | $136.91MM | $194.30MM | $229.43MM |
| Operating Cash Flow | $-87.02MM | $-88.85MM | $-161.90MM |
| Capital expenditure | $1.22MM | $1.33MM | $0.47MM |
| Investing Cash Flow | $2.11MM | $-71.08MM | $-49.94MM |
| Financing Cash Flow | $22.71MM | $142.21MM | $187.96MM |
| Earnings Per Share* | $-0.61 | $-0.62 | $-0.80 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.